Skip to main content
Premium Trial:

Request an Annual Quote

University of Maryland Pharmacy Expansion Includes Pharmacogenetics, Nanomedicine

NEW YORK (GenomeWeb News) – An addition to the Pharmacy Hall at the University of Maryland School of Pharmacy will include four floors of space dedicated to clinical and translational research in pharmacogenetics, nanomedicine, and drug discovery, the school said this week.
 
Maryland Governor Martin O'Malley and the Maryland legislature recently approved $62 million in funding for the addition, which will span seven stories and 92,635 square feet, the university said in a statement. It expects the new building to be open in time for the fall 2010 semester.
 
"In securing more than $62 million for the construction of the Pharmacy Hall addition, Gov. Martin O'Malley and the Maryland General Assembly have recognized the need to educate more pharmacists, carry out more cutting-edge research, and deepen our commitment to serve the community," said David Ramsay, president of the University of Maryland, Baltimore, where the pharmacy school is located.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.